BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lupkynis (Voclosporin) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Lupkynis (Voclosporin)\, from ClinicalTri
 als.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07225387-1793@assetmemo.bio
DTSTAMP:20261121T010010Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Lupkynis (Voclosporin): Phase 4 readout est. (NCT07225387)
DESCRIPTION:Lupkynis (Voclosporin)\, phase 4\, Systemic Lupus Erythematosus
 .\nStudy: Safety and Efficacy of Combination Belimumab and Voclosporin in 
 the Treatment of Proliferative Forms of Lupus Glomerulopathy: Synergy Tria
 l\nEstimated primary completion: January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/voclosporin#upcoming-events\nRegistry record: ht
 tps://clinicaltrials.gov/study/NCT07225387
URL:https://assetmemo.bio/drug/voclosporin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06406205-1793@assetmemo.bio
DTSTAMP:20261121T010010Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Lupkynis (Voclosporin): Phase 3 readout est. (NCT06406205)
DESCRIPTION:Lupkynis (Voclosporin)\, phase 3\, Systemic Lupus Erythematosus
 .\nStudy: A Study of QLG1074 Combined With Background Therapy in Subjects 
 With Active Lupus Nephritis\nEstimated primary completion: June 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/voclosporin#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT06406205
URL:https://assetmemo.bio/drug/voclosporin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07760480-1793@assetmemo.bio
DTSTAMP:20261121T010010Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Lupkynis (Voclosporin): Phase 4 readout est. (NCT07760480)
DESCRIPTION:Lupkynis (Voclosporin)\, phase 4\, Systemic Lupus Erythematosus
 .\nStudy: Assessing Residual Inflammation and Macrophage Presence in Lupus
  Nephritis After 3 Months of Intensified Treatment With Prednisolone\, Myc
 ofenolate Mofetil and Voclosporin as Compared to Mycofenolate Mofetil and 
 Prednisolone\nEstimated primary completion: April 2028. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/voclosporin#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07760480
URL:https://assetmemo.bio/drug/voclosporin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07611214-1793@assetmemo.bio
DTSTAMP:20261121T010010Z
DTSTART;VALUE=DATE:20290302
DTEND;VALUE=DATE:20290303
SUMMARY:Lupkynis (Voclosporin): Phase 4 readout est. (NCT07611214)
DESCRIPTION:Lupkynis (Voclosporin)\, phase 4\, Systemic Lupus Erythematosus
 .\nStudy: PRESERVE: LUPKYNIS in Combination With Belimumab\, Obinutuzumab 
 or Anifrolumab in Patients With Lupus Nephritis\nEstimated primary complet
 ion: 2 March 2029. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/vo
 closporin#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07611214
URL:https://assetmemo.bio/drug/voclosporin#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
